STTR: Preclinical Studies to Validate the Efficacy of Novel Mechanism-of-Action Small Molecule Inhibitors to Treat Duchenne Muscular Dystrophy

Grants and Contracts Details

StatusFinished
Effective start/end date2/1/20 → 8/31/22

Funding

  • Ridgeline Therapeutics: $139,852.00